Scarica l'app Stockscreener
54.20
29.26%
12.27
Dopo l'orario di chiusura:
55.00
0.80
+1.48%
Cg Oncology Inc Borsa (CGON) Ultime notizie
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026 - TechStock²
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target - TipRanks
CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up - MarketScreener
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighTime to Buy? - MarketBeat
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com India
CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com
Why CG Oncology Stock Is Sliding Despite Trial Boost - TipRanks
CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline - TipRanks
Cg Oncology provides updated timeline for Pivot-006 phase 3 topline data in intermediate-risk NMIBC - MarketScreener
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com India
CG Oncology, Inc. Announces Expedited Timeline for PIVOT-006 Phase 3 Data - TradingView — Track All Markets
CG Oncology Announces Expedited Timeline for Phase 3 PIVOT-006 Trial Data on Cretostimogene for Intermediate-Risk NMIBC - Quiver Quantitative
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - The Manila Times
Bladder cancer trial to deliver key results nearly a year early - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Nasdaq 100 Index Early-Stage Biotech - Kalkine Media
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is CG Oncology Inc. stock trading at a premium valuationJuly 2025 Spike Watch & AI Driven Price Forecasts - ulpravda.ru
Aktis raises $318M in 2026’s first biotech IPO - BioPharma Dive
Will CG Oncology Inc. stock split again soonQuarterly Portfolio Report & Weekly Breakout Watchlists - ulpravda.ru
Can CG Oncology Inc. stock maintain growth trajectoryJuly 2025 Highlights & Low Risk Profit Maximizing Plans - ulpravda.ru
Why analysts upgrade CG Oncology Inc. stockTake Profit Strategies & Free Robust Financial Gains - ulpravda.ru
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
CG Oncology (NASDAQ:CGON) Shares Down 6.3%Here's What Happened - MarketBeat
Midday Stock Roundup: Skyworks Solutions down 12% - Orange County Business Journal
Big Picture: Is CG Oncology Inc stock trading at a premium valuationEarnings Beat & Community Trade Idea Sharing Platform - moha.gov.vn
CG Oncology Earnings Notes - Trefis
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Piper Sandler initiates coverage of oncology companies - MSN
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
CG Oncology Appoints Christina Rossi to Board - MSN
CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha
CG Oncology, Inc. (CGON): Investor Outlook Reveals 76% Potential Upside In Biotech Stock - DirectorsTalk Interviews
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating - TipRanks
SUO-CTC CG Oncology NMIBC Research Fellowship - Oncodaily
Will CG Oncology Inc. stock continue upward momentum2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC DataWhat's Changed - Sahm
Why CG Oncology Inc. stock is in analyst buy zoneMarket Rally & Real-Time Volume Trigger Notifications - DonanımHaber
Is CG Oncology Inc. stock supported by strong cash flows2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will CG Oncology Inc. stock beat EPS estimatesJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Aug Summary: Why analysts upgrade CG Oncology Inc. stockChart Signals & Weekly High Return Opportunities - Улправда
Is CG Oncology Inc. stock a safe investment in uncertain marketsGold Moves & Low Risk Growth Stock Ideas - Улправда
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce the Second Annual - GlobeNewswire
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology Inc Stock Analysis and ForecastHigh Yield Income Stocks & Technical + Fundamental = Smarter Investing - earlytimes.in
CG Oncology appoints Rossi to its Board of Directors - MSN
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
CG Oncology initiated with an Outperform at Wedbush - TipRanks
Wedbush initiates coverage on CG Oncology stock with Outperform rating By Investing.com - Investing.com Canada
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Insider Monkey
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - Sahm
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):